Commercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical ...

FDA has previously agreed on the design of this 300-patient randomized, placebo-controlled confirmatory Phase 3 trial, and the 12-month primary endpoint of pain reduction as an approvable indication.

The aviation authority thanked passengers and airlines for their cooperation during what it described as a precautionary ...

Successful spine and orthopedic leaders constantly evolve with shifting mindsets and look past assumptions that may hold back ...

The value-based care and direct-to-employer payment models are gaining traction in both the orthopedic and spine spaces, but there are still some significant hurdles to industrywide adoption.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase ...

Mesoblast has reached its patient recruitment target for a pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain caused by degenerative disc disease, a key step toward potential ...

Commercial fishing in Maine is breaking the people who sustain it. Four out of five fishermen report overuse injuries — torn ...

Data demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- ...

Mesoblast Ltd (ASX: MSB) hits a key Phase 3 trial recruitment target in chronic low back pain, advancing towards FDA approval ...

Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesob ...

From assumptions about surgical volume to the role of anesthesiologists, ASC leaders discuss ideas they’ve unlearned in recent years. Note: These responses were lightly edited for clarity. Question: ...